Survivin in autoimmune diseases-Reference-Cited by-同舟云学术

Survivin in autoimmune diseases

Published:2017-08 Issue:8 Volume:16 Page:845-855
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Gravina G.,Wasén C.,Garcia-Bonete M.J.,Turkkila M.,Erlandsson M.C.,Töyrä Silfverswärd S.,Brisslert M.,Pullerits R.,Andersson K.M.,Katona G.,Bokarewa M.I.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference181 articles.

1. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma;Ambrosini;Nat Med,1997

2. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies;Caldas;Mol Cancer,2005

3. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties;Mahotka;Cancer Res,1999

4. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin;Ling;J Biol Chem,2007

5. Survivin-2B promotes autophagy by accumulating IKK alpha in the nucleus of selenite-treated NB4 cells;Shi;Cell Death Dis,2014

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K/Akt signaling pathway;Discover Oncology;2024-04-27

2. A promising future of metal‐N‐heterocyclic carbene complexes in medicinal chemistry: The emerging bioorganometallic antitumor agents;Medicinal Research Reviews;2024-04-09

3. SURVIVIN IN SYNERGY WITH BAF/SWI COMPLEX BINDS BIVALENT CHROMATIN REGIONS AND ACTIVATES DNA DAMAGE RESPONSE IN CD4+ T CELLS;2024-03-10

4. Lymphopenia associated with survivin and its downstream pathway in COVID-19 serving as a potential route in COVID-19 pathogenesis;Advances in Medical Sciences;2024-03

5. Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target;Journal of Drug Targeting;2024-02